These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15269493)

  • 1. Fenofibrate-induced myopathy.
    Ghosh B; Sengupta S; Bhattacharjee B; Majumder A; Sarkar SB
    Neurol India; 2004 Jun; 52(2):268-9. PubMed ID: 15269493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myopathy caused by a combination rosuvastatin and fenofibrate.
    Dedhia V; Munsi SC
    J Assoc Physicians India; 2007 Feb; 55():152-3. PubMed ID: 17571748
    [No Abstract]   [Full Text] [Related]  

  • 3. Rare side-effects of fenofibrate.
    Rabasa-Lhoret R; Rasamisoa M; Avignon A; Monnier L
    Diabetes Metab; 2001 Feb; 27(1):66-8. PubMed ID: 11240449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Muscular toxicity due to fenofibrate. Apropos of a case].
    Giraud P; Cassou M; Paul R; Guidet M
    Rev Rhum Mal Osteoartic; 1982 Feb; 49(2):162. PubMed ID: 7063798
    [No Abstract]   [Full Text] [Related]  

  • 5. Gynecomastia associated with fenofibrate.
    Gardette V; Vezzosi D; Maiza JC; Montastruc JL; Olivier P
    Ann Pharmacother; 2007 Mar; 41(3):508-10. PubMed ID: 17341535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of 12-week treatment with fenofibrate 300 mg in Thai dyslipidemic patients.
    Koanantakul B; Jeamanukulkit N; Piamsomboon C; Chawantanpipat C; Khanacharoen I
    J Med Assoc Thai; 2004 Nov; 87(11):1281-5. PubMed ID: 15825700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Myopathy caused by fenofibrate].
    Solsona L; Coll J; Ariza A; Olivé A
    Med Clin (Barc); 1991 Nov; 97(17):677. PubMed ID: 1762464
    [No Abstract]   [Full Text] [Related]  

  • 8. [Hypothyroidism and muscular toxicity from fenofibrate, report of a case revealed by polymyositis].
    Cherif O; Karma F; Ben Amor G; Kochbati S; Ben Amor B; Rokbani L
    Tunis Med; 1997 Feb; 75(2):87-91. PubMed ID: 9506029
    [No Abstract]   [Full Text] [Related]  

  • 9. [Necrotizing myopathy with antilipemic agents. Case report and review of the literature].
    Berger O; Zifko U; Jellinger K; Machacek E; Grisold W
    Nervenarzt; 1993 Aug; 64(8):539-44. PubMed ID: 8413753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fenofibrate for hypertriglyceridemia.
    Med Lett Drugs Ther; 1998 Jul; 40(1030):68-9. PubMed ID: 9664930
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
    Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).
    Grundy SM; Vega GL; Yuan Z; Battisti WP; Brady WE; Palmisano J
    Am J Cardiol; 2005 Feb; 95(4):462-8. PubMed ID: 15695129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Fenofibrate, efficacy and tolerance in long-term treatment (author's transl)].
    Fromantin M; Gautier D; Quatre JM; Bon R
    Therapie; 1981; 36(4):473-6. PubMed ID: 7292431
    [No Abstract]   [Full Text] [Related]  

  • 14. Fenofibrate and cardiovascular risk: a synopsis and commentary on (FIELD).
    Bailey CJ
    Diabet Med; 2006 Feb; 23(2):109-12. PubMed ID: 16433706
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term remission from gout associated with fenofibrate therapy.
    Hepburn AL; Kaye SA; Feher MD
    Clin Rheumatol; 2003 Feb; 22(1):73-6. PubMed ID: 12605325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cochleovestibular disorders and hyperlipidemia. A controlled trial with fenofibrate.
    Torossian F; Laredo C
    Monogr Atheroscler; 1986; 14():222-9. PubMed ID: 3526130
    [No Abstract]   [Full Text] [Related]  

  • 17. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate.
    Sacks FM
    Am J Cardiol; 2008 Dec; 102(12A):34L-40L. PubMed ID: 19084088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paradoxical decreases in high-density lipoprotein cholesterol with fenofibrate: a quite common phenomenon.
    Magee G; Sharpe PC
    J Clin Pathol; 2009 Mar; 62(3):250-3. PubMed ID: 19251953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fenofibrate-induced photosensitivity.
    Leenutaphong V; Manuskiatti W
    J Am Acad Dermatol; 1996 Nov; 35(5 Pt 1):775-7. PubMed ID: 8912578
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute renal failure secondary to fenofibrate monotherapy-induced rhabdomyolysis.
    Tahmaz M; Kumbasar B; Ergen K; Ure U; Karatemiz G; Kazancioglu R
    Ren Fail; 2007; 29(7):927-30. PubMed ID: 17994463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.